Research Analysts Issue Forecasts for Iradimed Corporation’s Q1 2024 Earnings (NASDAQ:IRMD)

Iradimed Corporation (NASDAQ:IRMD) – Equities research analysts at Roth Capital issued their Q1 2024 EPS estimates for shares of Iradimed in a research report issued to clients and investors on Monday, April 22nd. Roth Capital analyst J. Wittes forecasts that the medical equipment provider will post earnings per share of $0.31 for the quarter. Roth Capital has a “Buy” rating on the stock. The consensus estimate for Iradimed’s current full-year earnings is $1.42 per share. Roth Capital also issued estimates for Iradimed’s Q2 2024 earnings at $0.35 EPS, Q3 2024 earnings at $0.34 EPS, Q4 2024 earnings at $0.39 EPS, FY2024 earnings at $1.39 EPS and FY2025 earnings at $1.72 EPS.

Iradimed (NASDAQ:IRMD) last issued its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.36 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.01). The company had revenue of $17.45 million during the quarter. Iradimed had a return on equity of 24.62% and a net margin of 26.22%.

A number of other analysts have also weighed in on the stock. Roth Mkm restated a “buy” rating and set a $65.00 target price on shares of Iradimed in a research note on Monday. Singular Research reissued a “buy” rating on shares of Iradimed in a report on Monday, April 1st.

Iradimed Trading Down 2.3 %

Shares of IRMD stock opened at $41.47 on Thursday. The company’s 50-day moving average price is $42.81 and its 200-day moving average price is $43.01. The stock has a market cap of $525.01 million, a price-to-earnings ratio of 30.49 and a beta of 0.82. Iradimed has a twelve month low of $36.12 and a twelve month high of $51.04.

Institutional Trading of Iradimed

Several institutional investors have recently modified their holdings of the company. Shaker Investments LLC OH raised its position in Iradimed by 1.3% during the first quarter. Shaker Investments LLC OH now owns 20,258 shares of the medical equipment provider’s stock valued at $891,000 after buying an additional 258 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Iradimed by 0.5% during the 3rd quarter. Los Angeles Capital Management LLC now owns 53,301 shares of the medical equipment provider’s stock worth $2,365,000 after acquiring an additional 279 shares in the last quarter. Riverwater Partners LLC boosted its stake in shares of Iradimed by 2.5% during the 4th quarter. Riverwater Partners LLC now owns 11,931 shares of the medical equipment provider’s stock worth $566,000 after acquiring an additional 295 shares in the last quarter. Copeland Capital Management LLC bought a new stake in shares of Iradimed during the 3rd quarter worth about $30,000. Finally, Aristides Capital LLC boosted its stake in shares of Iradimed by 7.3% during the 4th quarter. Aristides Capital LLC now owns 9,873 shares of the medical equipment provider’s stock worth $469,000 after acquiring an additional 673 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.